Clinical Trial Update: VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination chemotherapy regimen (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) in patients with Extranodal NK-T-Cell Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• IFOSFAMIDE (IFOSFAMIDE)
• L-asparaginase (L-asparaginase)
• VP-16 (etoposide)

Snippet

Sponsor: Samsung Medical Center | Conditions: Extranodal NK-T-Cell Lymphoma | Phase 2 | Status: UNKNOWN